Schott Pharma AG & Co KGaA: Key Financial and Strategic Developments

Financial Overview

Schott Pharma AG & Co KGaA, a prominent player in the health care sector, is headquartered in Mainz, Germany. The company specializes in drug containment and delivery solutions, offering products such as prefillable syringes, cartridges, vials, and ampoules. These products cater to pharmaceutical companies, biotechs, and CDMOs globally. Schott Pharma is listed on the Xetra stock exchange, with its shares traded in EUR.

As of May 11, 2025, Schott Pharma’s close price was 26.25 EUR. The company’s stock has experienced significant volatility over the past year, with a 52-week high of 36.88 EUR on August 28, 2024, and a 52-week low of 18.5 EUR on April 6, 2025. The market capitalization stands at approximately 3.73 billion EUR, and the price-to-earnings ratio is 28.5167.

Upcoming Financial Disclosures

On Thursday, May 15, 2025, Schott Pharma AG & Co KGaA is scheduled to release its detailed half-year results. The announcement will be followed by an analyst conference at 11:00 AM. This disclosure is part of a broader schedule of financial results from various companies, including Allianz SE, Deutsche Telekom AG, and Siemens AG, among others.

Strategic Investment and Growth

In a significant development, Novo Holdings, a global life sciences investor, announced an investment in SCHOTT Poonawalla, a joint venture between SCHOTT Pharma AG and the Serum Institute of India. SCHOTT Poonawalla is recognized as India’s leading manufacturer of injectable-focused primary packaging, producing over 3 billion units annually across three manufacturing facilities.

This investment highlights Novo Holdings’ strategy to foster long-term partnerships with healthcare platforms in Asia and strengthens its presence in the pharmaceutical infrastructure segment. It marks Novo Holdings’ first venture into the Medtech manufacturing space in India, aligning with its global strategy to support category-defining life sciences platforms.

The investment is expected to accelerate growth and innovation in injectable drug packaging, with Novo Holdings committed to supporting SCHOTT Poonawalla’s expansion through value creation initiatives and sustained engagement.

Conclusion

Schott Pharma AG & Co KGaA continues to be a key player in the health care sector, with strategic investments and upcoming financial disclosures poised to shape its future trajectory. The company’s focus on innovation and expansion, particularly in the Asian market, underscores its commitment to maintaining a leading position in drug containment and delivery solutions.